INTRODUCTION
Granulocytic sarcoma (GS) is also known as myeloid sarcoma or chloroma because of its green hue caused by myeloperoxidase (MPO). This disease involves the localization of myeloblasts or immature myeloid cells to an extramedullary site. GS has been described at numerous anatomic sites, but cutaneous GS (CGS) is uncommon. Although CGS is rare, it is clearly associated with myeloid disorders, such as acute myeloid leukemia, myeloproliferative neoplasms, and myelodysplastic syndromes (MDSs). CGS may herald acute transformation, and it is associated with a poor prognosis. [1] [2] [3] However, the mechanism underlying the specific migration of myeloblasts to the skin remains uncertain. In 2008, Kawakami et al 4 presumed that transforming growth factorebeta 1 (TGF-b1) released by hematopoietic cells within the cutaneous extramedullary hematopoiesis could play a role in the onset of such skin lesions. 4 We report a case of a patient with MDS presenting with 2 CGSs that developed consecutively at traumatized skin sites, suggestive of the Koebner phenomenon (KP). Immunohistochemical (IHC) analysis confirmed the expression of TGF-b1 on myeloblasts and fibroblasts that had infiltrated the CGSs but also showed the expression of its specific receptor (TGF-b1R), suggesting a role for this cytokine in cutaneous tropism and the pathogenesis of the KP.
CASE REPORT
A 77-year-old man was admitted to our dermatology department with fevers and a 1-month history of a hematoma on the left thigh, evolving in an indurated necrotizing ulcerative plaque (Fig 1) . MDS was diagnosed 18 months prior (refractory anemia with excess blasts I, normal molecular cytogenetics, trisomy 8 in the tumoral clone), which was treated with norethandrolone. A complete blood count on admission showed hemoglobin at 8.2 g/dL (normal ranges, 12.4-14.9 g/dL), platelet level at 28 G/L (normal ranges, 150-400 G/L), a leukocytosis count at 5. 8 (Fig 1, B and C) . A supplementary IHC analysis found that TGF-ß1 and its specific receptor, TGF-ß1R, were highly expressed in immature hematopoietic cells and dermal fibroblasts within the GS (Fig 2, A and B) . The cutaneous lesion had completely resolved 3 weeks after the resolution of fevers, and the blood count normalized after treatment with antibiotics (cloxacillin for 18 days, 1 g 3 times per day). Skin biopsy results confirmed the complete regression of the GS.
Several days later, complete excision of a squamous cell carcinoma located on the cheek was performed. No myeloblasts were observed by histologic examination of this lesion. However, during the wound healing process (10 days after surgery), a second GS was identified as a purple plaque that had infiltrated and ulcerated around the surgical wound (myeloblasts identified as CD45 1 , MPO 1 , MiB1 1 , and CD34 À ; Fig 3) . Similar to the first GS detected, expression of TGF-ß1 and TGF-ß1R was observed on myeloblasts and dermal fibroblasts within the GS (Fig 2, C and D) . Complete and spontaneous regression of the lesion was observed 3 weeks later.
Eighteen months later, the patient was still alive and had received chemotherapy treatment, which had been initiated after his GS episodes (3 rounds of cytarabine/mitoxantrone) but did not cure his MDS. Cutaneous surgery was avoided, and no skin lesions were observed. No additional GS was diagnosed.
DISCUSSION
We describe 2 episodes of CGS that occurred after trauma (hematoma and cutaneous surgery) in the context of MDS. The differential diagnosis included pyoderma gangrenosum (PG) and aleukemic leukemia cutis. PG, the most common neutrophilic dermatosis described in MDS, was excluded based on several clinical and histopathologic characteristics. 5 Clinically, the lesions did not start as papules or pustules, were asymptomatic, and were not associated with constitutional symptoms. Histologically, the infiltrate of cells was dense in the junction between dermis and subcutis and composed of myeloblasts rather than a massive dermal-epidermal neutrophilic infiltrate with suppuration/abscess formation as in PG. Aleukemic leukemia cutis was excluded based on the absence of leukemic evolution 2 years after the skin lesions developed and the negativity of CD34 and CD117 stains on infiltrated blast cells.
This type of GS resulting from skin trauma is termed the KP or isomorphic response. The KP has been associated classically with dermatologic diseases (eg, psoriasis, lichen sclerosus), but it has also been described in association with systemic diseases. 6 Some cases of GS occurring after a trauma have been reported that did not result from the KP, such as a GS that developed in a preexisting hydroxyurea-induced leg ulcer in a polycythemia vera patient and a GS masquerading as a perianal abscess. 7, 8 Furthermore, a ''pseudoKoebner'' response was reported in an MDS patient, but the absence of hematopoietic cells in the skin biopsies did not allow for the verification of this case as the true KP. 9 In our case, the hematopoietic cells detected in the skin biopsies during the wound healing process were suggestive of the KP. Similar to GS, the pathogenesis of the KP remains obscure and has not been extensively studied. However, involvement of inflammatory cells and local production of various cytokines and adhesion molecules have been suspected. 6 The expression of chemokine receptors, cytokines, and adhesion molecules by myeloblasts and various skin cells could explain the localization of GS to the skin. Byrd et al 10 found that the expression of CD56, an adhesion molecule, on blast cells was a risk factor for extramedullary tumors in one MDS case. In our case, IHC analysis of skin samples found overexpression of the TGF-b1/TGF-b1R pathway in immature hematopoietic cells and dermal fibroblasts during cutaneous extramedullary hematopoiesis. Only expression of TGF-b1 in association with MDS was reported in the literature to date. 4 TGF-b1 has long been recognized as a key molecule acting both during wound repair and tumor formation. Indeed, it is a growth factor synthesized by skin cells (eg, keratinocytes, fibroblasts) and actively participates in the skin wound healing process by increasing the inflammatory response, promoting both myofibroblast activation and survival and extracellular matrix remodeling. 11, 12 Thus, it was not surprising to find TGF-b1 in our case, but its expression on myeloblasts within the GS suggested that this cytokine could be involved in the onset of CGS. In MDS, the TGF-b1 pathway is constitutively activated in MDS progenitors, suggesting that these hematopoietic cells are more sensitive to this cytokine. 12 In any event, novel therapeutics targeting the TGF-b1 pathway to regulate or inhibit its constitutive activation of MDS progenitors have been reported for the treatment of MDS. Furthermore, TGF-b1 plays a central role in tumor development by facilitating the extravasation of metastasizing tumor cells. 11 These data suggest that TGF-b1, which is produced by cancer cells and skin cells (eg, fibroblasts, immune cells), is able to create a microenvironment that promotes the induction of cancer cell migration and GS formation, thereby explaining the KP.
The spontaneous regression of the 2 GSs in this case may be explained by the negative feedback of the amplification loop operated by TGF-b1 or normalization of the TGF-b1 pathway during the skin wound healing process. The exact role of TGF-b1 and its specific receptor remains to be clearly elucidated.
